Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Abhimanyu Gowda

BA (Hons) Natural Sciences

DPhil Student

DPhil Student (Medical Sciences)

Social media

I am a DPhil student in the Vyas Laboratory, additionally supervised by Ricardo Fernandes (Nuffield Department of Medicine, China-Oxford Institute). 

Previously I graduated with a first-class degree in Natural Sciences from the University of Cambridge (Christ's College). I focused my study on Molecular and Cellular Pathology, working with Prof. Ming Du to explore the mutational profile of B-cell lymphoproliferative disorders such as IPSID and primary cold agglutinin disease. I have also worked with Saar Gill (University of Pennsylvania), where I assisted with investigation into the use of CRISPR base-editing in enabling new immunotherapies. 

My current work focuses on profiling the molecular basis for the allograft effect against minor histocompatibility antigens in acute myeloid leukaemia (AML). I am interested in understanding how specific pMHC-TCR interactions lead to potent recognition of GvL antigens and subsequent rejection of AML tissue by donor T-cells. To do this, I am utilising protein engineering and molecular biology techniques to probe the biophysical interaction between peptide, HLA, and TCR alleles identified to be of interest from studies in AML patients.

I am also interested in how such sequence and structural properties of the pMHC-TCR axis can drive certain T-cell subsets to adopt a persistent, cytotoxic fate that is associated with excellent responses in patients receiving transplant or T-cell therapies. I will be exploring how such concepts can be applied more generally to cancer immunology approaches, including in the context of solid and epithelial malignancies.